Snyder Capital Management LP Has Cut Halozyme Therapeutics (HALO) Position by $1.05 Million; Advantus Capital Management Boosted Its Brixmor Property Group (BRX) Position by $1.39 Million as Stock Price Declined

January 1, 2018 - By Adrian Erickson

Snyder Capital Management LP decreased its stake in Halozyme Therapeutics Inc (HALO) by 2.44% based on its latest 2017Q3 regulatory filing with the SEC. Snyder Capital Management LP sold 61,778 shares as the company’s stock rose 2.38% with the market. The institutional investor held 2.47M shares of the health care company at the end of 2017Q3, valued at $42.85 million, down from 2.53M at the end of the previous reported quarter. Snyder Capital Management LP who had been investing in Halozyme Therapeutics Inc for a number of months, seems to be less bullish one the $2.86B market cap company. The stock decreased 2.17% or $0.45 during the last trading session, reaching $20.26. About 760,457 shares traded. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 44.89% since January 1, 2017 and is uptrending. It has outperformed by 28.19% the S&P500.

Advantus Capital Management Inc increased its stake in Brixmor Property Group Inc (BRX) by 10.91% based on its latest 2017Q3 regulatory filing with the SEC. Advantus Capital Management Inc bought 77,400 shares as the company’s stock declined 20.44% while stock markets rallied. The institutional investor held 786,900 shares of the real estate investment trusts company at the end of 2017Q3, valued at $14.79 million, up from 709,500 at the end of the previous reported quarter. Advantus Capital Management Inc who had been investing in Brixmor Property Group Inc for a number of months, seems to be bullish on the $5.70 billion market cap company. The stock increased 0.97% or $0.18 during the last trading session, reaching $18.66. About 1.44 million shares traded. Brixmor Property Group Inc. (NYSE:BRX) has declined 24.49% since January 1, 2017 and is downtrending. It has underperformed by 41.19% the S&P500.

Advantus Capital Management Inc, which manages about $27.77 billion and $3.85 billion US Long portfolio, decreased its stake in Sunstone Hotel Investors Inc (NYSE:SHO) by 59,600 shares to 592,200 shares, valued at $9.52M in 2017Q3, according to the filing. It also reduced its holding in Liberty Property Trust (NYSE:LPT) by 25,100 shares in the quarter, leaving it with 407,584 shares, and cut its stake in Avalonbay Communities Inc (NYSE:AVB).

Investors sentiment increased to 1.57 in Q3 2017. Its up 0.04, from 1.53 in 2017Q2. It is positive, as 19 investors sold BRX shares while 74 reduced holdings. 39 funds opened positions while 107 raised stakes. 293.48 million shares or 3.16% less from 303.07 million shares in 2017Q2 were reported. Wolverine Asset Mgmt Limited Liability Corporation reported 0.02% stake. Aqr Mgmt Ltd Limited Liability Company has invested 0.02% in Brixmor Property Group Inc. (NYSE:BRX). Parametric Portfolio Associates Ltd Liability holds 0.01% of its portfolio in Brixmor Property Group Inc. (NYSE:BRX) for 671,687 shares. New York State Teachers Retirement Systems has invested 0% in Brixmor Property Group Inc. (NYSE:BRX). The France-based Natixis has invested 0.07% in Brixmor Property Group Inc. (NYSE:BRX). Glenmede Co Na stated it has 0.08% in Brixmor Property Group Inc. (NYSE:BRX). Moreover, California Employees Retirement Systems has 0.01% invested in Brixmor Property Group Inc. (NYSE:BRX) for 505,005 shares. Tiaa Cref Invest Ltd Liability holds 1.34M shares. 7.05 million are owned by Cbre Clarion Securities Limited Liability. Teacher Retirement System Of Texas holds 895,082 shares or 0.1% of its portfolio. Dimensional Fund Advisors Lp holds 4.48 million shares or 0.04% of its portfolio. 133,950 were reported by Manning And Napier Ltd Co. Northpointe Capital Ltd Liability reported 142,017 shares or 0.29% of all its holdings. Amer Grp owns 13,251 shares for 0% of their portfolio. 50,975 were reported by Rafferty Asset Mgmt Limited.

Among 18 analysts covering Brixmor Property Group (NYSE:BRX), 9 have Buy rating, 0 Sell and 9 Hold. Therefore 50% are positive. Brixmor Property Group had 46 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Brixmor Property Group Inc. (NYSE:BRX) earned “Overweight” rating by JP Morgan on Friday, December 16. The stock has “Buy” rating by Mizuho on Monday, August 14. The rating was maintained by RBC Capital Markets on Monday, November 6 with “Hold”. Stifel Nicolaus upgraded Brixmor Property Group Inc. (NYSE:BRX) on Monday, August 15 to “Buy” rating. The firm earned “Hold” rating on Monday, July 31 by RBC Capital Markets. The firm has “Hold” rating by Zacks given on Friday, August 7. The firm has “Hold” rating given on Monday, September 11 by BMO Capital Markets. As per Tuesday, July 19, the company rating was maintained by Barclays Capital. The rating was downgraded by Barclays Capital to “Equal-Weight” on Tuesday, February 9. The company was maintained on Tuesday, September 8 by Evercore.

Analysts await Halozyme Therapeutics, Inc. (NASDAQ:HALO) to report earnings on February, 27. They expect $0.67 earnings per share, up 419.05% or $0.88 from last year’s $-0.21 per share. HALO’s profit will be $94.51M for 7.56 P/E if the $0.67 EPS becomes a reality. After $0.02 actual earnings per share reported by Halozyme Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 3,250.00% EPS growth.

Among 8 analysts covering Halozyme Therapeutics (NASDAQ:HALO), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Halozyme Therapeutics had 18 analyst reports since August 11, 2015 according to SRatingsIntel. BMO Capital Markets maintained Halozyme Therapeutics, Inc. (NASDAQ:HALO) on Friday, September 15 with “Market Perform” rating. Piper Jaffray maintained Halozyme Therapeutics, Inc. (NASDAQ:HALO) on Wednesday, August 9 with “Buy” rating. The rating was maintained by Piper Jaffray on Friday, September 16 with “Overweight”. The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) has “Market Perform” rating given on Wednesday, November 8 by BMO Capital Markets. The rating was initiated by Barclays Capital on Tuesday, September 22 with “Overweight”. The rating was maintained by Barclays Capital on Wednesday, February 24 with “Overweight”. As per Friday, September 15, the company rating was maintained by Deutsche Bank. Piper Jaffray maintained the shares of HALO in report on Thursday, September 14 with “Buy” rating. The firm earned “Hold” rating on Wednesday, November 22 by Barclays Capital. The firm earned “Outperform” rating on Friday, December 4 by Wells Fargo.

Snyder Capital Management L P, which manages about $2.16 billion and $2.00 billion US Long portfolio, upped its stake in Medtronic Plc (NYSE:MDT) by 5,678 shares to 34,102 shares, valued at $2.65 million in 2017Q3, according to the filing. It also increased its holding in Analog Devices Inc (NASDAQ:ADI) by 8,471 shares in the quarter, for a total of 33,947 shares, and has risen its stake in Genesee & Wyo Inc (NYSE:GWR).